This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

David L. Dunn, MD, PhD; Brian P. Priest, MD; Richard M. Condie

Arch Surg. 1988;123(11):1389-1393.

Abstract
• Both monoclonal antibody (MAb) and polyclonal antibody (PAb) directed against the shared core/lipid A region of lipopolysaccharide (LPS) (endotoxin) provide protection during experimental gram-negative bacterial sepsis. Although these preparations have not been compared, clinical trials administering either preparation to septic patients have been instituted. The core/lipid A region of LPS represents an antigenic domain common to many, if not all, gram-negative microbes, and thus represents an ideal target site for antibody binding. We sought to determine (1) the protective capacity of similarly reactive IgG anti—core LPS/lipid A MAbs and PAbs, (2) whether the timing of administration was important, and (3) whether either would act additively with antimicrobial agents. Antibody was administered intravenously to outbred mice, and Escherichia coli 0111:B4 was then administered intravenously or intraperitoneally with hemoglobin. Monoclonal antibodies and PAbs were equally protective, and protection was maximized by pretreatment, although the effect extended to four hours after bacterial challenge. Both MAbs and PAbs acted in concert with gentamicin hydrochloride to further reduce lethality. We concluded that MAbs and PAbs were equally protective and that clinical utility may eventually be dictated by ease and cost of antibody production.

(Arch Surg 1988;123:1389-1393)

Author Affiliations
From the Department of Surgery, University of Minnesota, Minneapolis.

Footnotes
Accepted for publication June 28, 1988.

Read before the Eighth Annual Meeting of the Surgical Infection Society, San Francisco, May 6, 1988.

Reprint requests to Box 242 Mayo Memorial Building, University of Minnesota, Minneapolis, MN 55455 (Dr Dunn).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Review: Evidence against the hypothesis that antibodies to the inner core of lipopolysaccharides in antisera raised by immunization with enterobacterial deep-rough mutants confer broad-spectrum protection during Gram-negative bacterial sepsis
Greisman and Johnston
Innate Immunity 1997;4:123-153.
ABSTRACT  

Inhibition of Splenic Macrophage Tumor Necrosis Factor {alpha} Secretion In Vivo by Antilipopolysaccharide Monoclonal Antibodies
Battafarano et al.
Arch Surg 1994;129:179-186.
ABSTRACT  

Review: Experimental and Clinical Applications of Molecular Cell Biology in Nutrition and Metabolism
Yuman Fong et al.
JPEN J Parenter Enteral Nutr 1992;16:477-486.
ABSTRACT  

Decreased Tumor Necrosis Factor Production During the Initial Stages of Infection Correlates With Survival During Murine Gram-negative Sepsis
Mayoral et al.
Arch Surg 1990;125:24-28.
ABSTRACT